Michael Patrick Donovan - 16 Mar 2024 Form 4 Insider Report for Axogen, Inc. (AXGN)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
25 Mar 2024, 21:22:54 UTC
Prior SEC filing
08 Mar 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Marc Began by Power of Attorney for Mike Donovan

Key filing fact

Michael Patrick Donovan filed Form 4 for Axogen, Inc. (AXGN) on 25 Mar 2024.

Key facts

  • This page summarizes Michael Patrick Donovan's Form 4 filing for Axogen, Inc. (AXGN).
  • 9 reported transactions and 3 derivative rows are listed below.
  • Accepted by SEC: 25 Mar 2024, 21:22.

Change

  • Previous filing in this sequence was filed on 08 Mar 2024.
  • Current net transaction value: -$46,333.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AXGN transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+3,000
Change %
+8.4%
Price
$0.000000
Shares after
38,708
Date
16 Mar 2024
Ownership
Direct
Footnotes
F1
AXGN transaction

Common Stock

Sale

Transaction value
$5,499
Shares
-716
Change %
-1.8%
Price
$7.68
Shares after
37,992
Date
21 Mar 2024
Ownership
Direct
Footnotes
F2
AXGN transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+2,950
Change %
+7.8%
Price
$0.000000
Shares after
40,942
Date
16 Mar 2024
Ownership
Direct
Footnotes
F1
AXGN transaction

Common Stock

Sale

Transaction value
$5,537
Shares
-721
Change %
-1.8%
Price
$7.68
Shares after
40,221
Date
21 Mar 2024
Ownership
Direct
Footnotes
F2
AXGN transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+18,625
Change %
+46%
Price
$0.000000
Shares after
58,846
Date
16 Mar 2024
Ownership
Direct
Footnotes
F1
AXGN transaction

Common Stock

Sale

Transaction value
$35,297
Shares
-4,596
Change %
-7.8%
Price
$7.68
Shares after
54,250
Date
21 Mar 2024
Ownership
Direct
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AXGN transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
$0
Shares
-3,000
Change %
-100%
Price
$0.000000*
Shares after
0
Date
16 Mar 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,000
Exercise price
Footnotes
F3, F4
AXGN transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
$0
Shares
-2,950
Change %
-50%
Price
$0.000000
Shares after
2,950
Date
16 Mar 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
2,950
Exercise price
Footnotes
F3, F5
AXGN transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
$0
Shares
-18,625
Change %
-50%
Price
$0.000000
Shares after
18,625
Date
16 Mar 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
18,625
Exercise price
Footnotes
F3, F6
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Michael Patrick Donovan is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 6 footnotes

Footnote F1

This reflects the number of restricted stock units that became vested as of March 16, 2024.

Footnote F2

Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

Footnote F3

Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock.

Footnote F4

All shares of Axogen Inc. common stock underlying the restricted stock units vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

Footnote F5

All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date.

Footnote F6

All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .